Sharda Ramsaroop, MD
Geriatric Medicine · New York, NYNPI 1043290208
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 24.8% of the total. Reporting peaked in 2023 at $765 and has fallen 83.7% since, to $125 in 2025. Among geriatric medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$615
- AstraZeneca$325
- Novo Nordisk$323
- Abbott$191
- Otsuka America Pharmaceutical, Inc.$125
- Merck$110
- plus $794 from 16 others
What the payments were for
- Food & beverage$2,471100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 45 | $615 |
| AstraZeneca | 20 | $325 |
| Novo Nordisk | 16 | $323 |
| Abbott | 12 | $191 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Merck | 6 | $110 |
| Astellas Pharma US Inc | 6 | $107 |
| Amgen | 5 | $105 |
| AbbVie | 5 | $100 |
| Lilly USA, LLC | 5 | $92 |
| Johnson & Johnson | 4 | $76 |
| Boehringer Ingelheim | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Pfizer | 3 | $45 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Dermira, Inc. | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$125
How this compares
$2,483 in reported general payments places this provider in the 90th percentile of 400 geriatric medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $42,617 |
| OzempicSemaglutide | 15 | $26,515 |
| MounjaroTirzepatide | 11 | $16,387 |
| XareltoRivaroxaban | 11 | $15,637 |
| TradjentaLinagliptin | 11 | $10,850 |
| SynthroidLevothyroxine Sodium | 18 | $2,184 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,615 |
| Lidocaine | 17 | $1,577 |
| Rosuvastatin Calcium | 50 | $971 |
| Metoprolol Succinate | 64 | $938 |
| Levothyroxine Sodium | 70 | $927 |
| Atorvastatin Calcium | 94 | $850 |
| Donepezil Hcl | 15 | $779 |
| Hydrocortisone | 17 | $651 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $45 | $42,61727 claims |
| Novo NordiskOzempic | $323 | $26,51515 claims |
| Lilly USA, LLCMounjaro | $92 | $16,38711 claims |
| Johnson & JohnsonXarelto | $76 | $15,63711 claims |
| Boehringer IngelheimTradjenta | $48 | $10,85011 claims |
| AbbVieSynthroid | $100 | $2,18418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 geriatric medicine providers in New York.
Other geriatric medicine in New York
- Howard FillitNew York$42K
- Alexandra FingestenNew York$9K
- Lisa BabitzNew York$6K
- Laszlo FeherNew York$4K
- Eric ManheimerNew York$3K
- Sofya KleynNew York$2K
- Eileen CallahanNew York$2K
- Wen DombrowskiBrooklyn$45K
- Sharon BrangmanSyracuse$45K
- Adam CohenGreat Neck$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.